Syndecan-1 as a prognostic biomarker in COVID-19 patients: a retrospective study of a Japanese cohort

Kiyohito Hayashi,Daisuke Koyama,Yoichi Hamazaki,Takamichi Kamiyama,Shingo Yamada,Miki Furukawa,Yoshinori Tanino,Yoko Shibata,Takayuki Ikezoe
DOI: https://doi.org/10.1186/s12959-024-00619-2
2024-06-22
Thrombosis Journal
Abstract:The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact, with millions of confirmed cases and deaths worldwide. While most cases are mild, a subset progresses to severe respiratory complications and death, with factors such as thromboembolism, age, and underlying health conditions increasing the risk. Vascular endothelial damage has been implicated in severe outcomes, but specific biomarkers remain elusive. This study investigated syndecan-1 (SDC-1), a marker of endothelial damage, as a potential prognostic factor for COVID-19, focusing on the Japanese population, which is known for its aging demographics and high prevalence of comorbidities.
peripheral vascular disease,hematology
What problem does this paper attempt to address?